LabCorp quarterly revenue beats on higher demand for COVID-19 testing

(Adds details on the quarter, estimates, shares)

July 28 (Reuters) - Laboratory Corporation of America Holdings on Tuesday reported better-than-expected sales for the second quarter, as higher demand for its COVID-19 tests more than offset the decline in other routine and specialty diagnostic testing.

The Burlington, North Carolina-based diagnostic testing company's shares were up 3.4% at $208 premarket, in very light volume.

The health crisis, which has so far infected more than 4 million Americans, has forced patients to delay non-essential medical procedures and tests associated with them as well as routine tests, which led to a decline in testing volumes for commercial labs.

LabCorp's diagnostics segment revenue fell 3.9% to $1.69 billion in the quarter. This was, however, offset by strong demand for its COVID-19 tests.

The company said it was currently processing about 180,000 COVID-19 tests per day.

It also reported a $55.9 million government stimulus income related to the Coronavirus Aid, Relief, and Economic Security (CARES) Act in the reported quarter.

Company reported net revenue of $2.77 billion, beating market estimates of $2.50 billion, as per Refinitiv data. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli) Keywords: LABORATORY CORP RESULTS/ (UPDATE 1)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.